AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04945278 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EASE test
Description: The patient will have to answer the EASE test which is a specific test to detect patient with high risk of psychosis or schizophrenia
Study NCT05131867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nimodipine
Description: (60 mg/4 hours) orally or via nasogastric tube
Study NCT05131867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nimodipine and milrinone
Description: Oral Nimodipine then after the diagnosis of vasospasm is confirmed, start milrinone bolus
Study NCT06014606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral formulation
Study NCT06014606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol 2mg
Description: oral formulation
Study NCT06014606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol 40mg
Description: oral formulation
Study NCT06800521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed Reality Breastfeeding Education
Description: Mixed Reality Breastfeeding Education:~This intervention includes an innovative mixed reality-based educational strategy combined with traditional breastfeeding counseling. Participants use mixed reality goggles to experience immersive breastfeeding scenarios, interact with audio-visual materials tailored for breastfeeding education, and engage with realistic breastfeeding simulations. The session is delivered once during the third trimester of pregnancy and lasts approximately 90 minutes. This intervention is designed to improve maternal confidence, satisfaction, and adherence to exclusive breastfeeding through an engaging and practical learning environment.
Study NCT06800521 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Breastfeeding Counseling
Description: This intervention involves standard prenatal breastfeeding education provided by trained healthcare professionals. Participants receive verbal and visual explanations of breastfeeding techniques, benefits, and solutions to common challenges. Delivered in a single session during the third trimester of pregnancy, the session lasts approximately 60 minutes and represents the current standard of care in breastfeeding education.
Study NCT06801990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: S1 transforaminal epidural steroid(dexamethasone) injection
Description: The designed study will examine the effect of oblique entry angles on contrast distribution patterns and treatment outcomes. Therefore, it aims to compare the smallest and largest angles that can be achieved under co-axial imaging at the S1 foramen. For this purpose, patients will be divided into two groups through randomization using a computer program. In the first group, after angling cranially and visualizing the foramen, the needle entry point will be determined. In the second group, after achieving optimal imaging by cranially angling the C-arm fluoroscope, an additional ipsilateral oblique angle will be applied to the fluoroscope.~In this context, Plastaras et al. reported that an angle of 5° ± 5° is the most suitable range for the S1 foramen. Additionally, another study examining dorsal and ventral S1 foramen via tomography images found that the average angle providing the widest view of the dorsal foramen was 26.6° ± 3°. In the current study, no oblique angle will be applied
Study NCT06801808 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myosave
Description: Nutritional supplementation with Myosave
Study NCT06801470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-001
Description: CD-001 administered as an intravenous (IV) infusion.
Study NCT06801275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 shower with 4% chlorhexidine gluconate
Description: Comparison of the effect of showering once with 4% Chlorhexidine Gluconate before lumbar disc herniation surgery on surgical site infections
Study NCT06801275 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2 shower with 4% chlorhexidine gluconate
Description: Comparison of the effect of showering twice with 4% Chlorhexidine Gluconate before lumbar disc herniation surgery on surgical site infections
Study NCT06800742 — intervention group
Intervention type: OTHER
Intervention: Collection of anthropometric and biochemical parameters
Description: Collection of anthropometric parameters biochemical parameters basal metabolic rate body composition questionnaires
Study NCT06802042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with probiotic bacteria
Description: The intervention group (n=20) received free intervention with probiotic bacteria (Lactobacillus reuteri DSM 8 +) for 4 weeks (1 bag bid)
Study NCT06802042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose oral solution treatment
Description: The control group (n=20) received lactulose oral solution free of charge for 4 weeks (1-2 bags qd for the first three days, and then increased or reduced according to constipation)
Study NCT06801249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metarapone
Description: Metirapone is an inhibitor of the enzyme 11-β-adrenal hydroxylase, which is deputed to catalyze the conversion of 11-desoxycortisol (11-S) to cortisol and 11-deoxycorticosterone (DOC) to corticosterone.
Study NCT06801249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized antihypertensive therapy
Description: Standardized antihypertensive therapy, as provided in the normal course of care and in accordance with current European guidelines.
Study NCT06800833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat cookies
Description: To determine the effects of low fat cookie consumption on physiological indicators of sexual, mental, skin, and gut health
Study NCT06800833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango
Description: To determine the effects of mango consumption on physiological indicators of sexual, mental, skin, and gut health
Study NCT06801600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Weight-based dosing
Description: Hyperbaric bupivacaine 0.5% dosage will be calculated and administered intrathecally as 0.4 mg/kg or 0.08 ml/kg if body weight ≤ 15 kg and 0.3 mg/kg or 0.06 ml/kg if body weight > 15 kg
Study NCT06801600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Age-based dosing
Description: Hyperbaric bupivacaine 0.5% will be administered at the dose of age divided by 5 (in ml). The age in months after the completion of a year was noted and considered as the next age if it is more than 6 months and the same age if it is ≤ 6 months.
Study NCT06800859 — intervention group
Intervention type: DRUG
Intervention: Supplement fluids
Description: To ensure optimal recovery and manage potential complications, patients are advised to supplement fluids by increasing their oral intake or receiving intravenous fluids as necessary. Bed rest is recommended to reduce physical strain and promote healing. Additionally, a blood patch procedure may be performed to alleviate symptoms such as headaches that can occur after certain medical procedures, particularly spinal taps. This involves injecting a small amount of the patient's own blood into the epidural space to seal any leaks of cerebrospinal fluid, thereby providing relief and aiding in recovery. Proper monitoring and follow-up care are essential to ensure the effectiveness of these interventions
Study NCT06801132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-delivered death anxiety intervention
Description: The online self-guided death anxiety intervention developed in this study is based on the Death Education and CBT framework. It took approximately two hours to complete the full intervention. The main content includes:~1. Emotional reactions and behavioral manifestations about death, fear management theories, and Chinese cultural attitudes toward death;~2. Imagine what you would like to say to yourself at the end of your life, and learn about various attitudes towards death through numerous examples;~3. Expressive writing, with moderate emotional exposure to stimulate reflection, accompanied by breathing exercises and positive thinking about death, to improve tolerance and control of death anxiety, and finally to correct biased perceptions by examining bad beliefs about death;~4. Prioritize the importance of things and make a practical action plan to enrich your life.
Study NCT06801132 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting-List (WL) condition
Description: Participants assigned to WL will be asked not to use our death anxiety intervention or seek additional help related to death anxiety during the 1-week intervention period. After the one-month follow-up of the experimental group, the WL group will receive the same intervention for death anxiety. WL participants will also be given contact information to use in case of increasing distress.
Study NCT06801652 — intervention group
Intervention type: OTHER
Intervention: Sperm morphology indexes
Description: We analyzed all sperm morphology indexes in all groups.
Study NCT06801509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose
Description: Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;
Study NCT06801509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose
Description: Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;
Study NCT06801509 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control: Saline
Description: The placebo in this study is 0.9% sodium chloride (normal saline) injection; Immunization procedure: 2 doses, 60 days apart;
Study NCT06801509 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix®
Description: Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Dosage of vaccination: 50 μg; Immunization procedure: 2 doses, 60 days apart
Study NCT06801509 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ganwei®
Description: Route of vaccination: subcutaneous injection into the lateral deltoid of the upper arm; Dosage of vaccination: 0.5 mL; Immunization procedure: saline will be administered at Day 0, and Ganwei® will be administered at Day 60；
Study NCT06800937 — intervention group
Intervention type: OTHER
Intervention: Determination of sphingolipidomic profile
Description: The plasma/serum levels of the following sphingolipids will be measured: ceramides and dihydroceramides from C16 to C24, including 2 unsaturated ones (C18:1 and C24:1), sphingomyelins (those from C16 to C24 and the one C24:1), sphingosine, sphinganine, sphingosine-1-phosphate and sphinganine-1-phosphate.
Study NCT06801171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive stimulation
Description: 12 sessions (one per week for 12 weeks) in group of cognitive stimulation
Study NCT06801171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed intervention
Description: 12 sessions (one per week for 12 weeks) in group of mixte stimulation (yoga, cognitive behavioral therapy, mindfullness meditation, positive psychology)
Study NCT06801106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella
Description: is an airway clearance device that combines the resistive features of a positive expiratory pressure device with oscillations, which diminishes the mucus adhesiveness and decrease the collapsibility of airways
Study NCT06801106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung flute
Description: is a new oscillatory positive expiratory pressure (OPEP) device that produces a low frequency acoustic wave with vigorous exhalation that increases mucociliary clearance
Study NCT06800807 — intervention group
Intervention type: OTHER
Intervention: Observation of several factors involved in eating and nutrition disorders
Description: Observation of symptomatology of eating and nutrition disorders, metacognitive beliefs, brooding and rumination.
Study NCT06800378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Description: Zolpidem tartrate 10 mg tablet (taken before bedtime)
Study NCT06800378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Starch 10 mg tablet (taken before bedtime)
Study NCT06801028 — intervention group
Intervention type: BIOLOGICAL
Intervention: injection Sekucinumab
Description: All patients with erythrodermic psoriasis (EP), who will receive subcutaneous injection of secukinumab at a dose of 300 mg once a week from week 0 to 4 followed by every 4 week. At weeks 0, 4, 8, 12, 16 and 20 the psoriasis area and severity index (PASI) will be recorded and adverse drug reactions, patient's satisfaction and recurrence will be observed.
Study NCT06801561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: This group will be subjected to laser therapy. Er,Cr:YSGG will be used (Waterlase®, Biolase, USA) of a wavelength of 2780 nm at a power of 0.75 W using a frequency of 20 Hz and pulse duration of 140 µs. (33) Irradiation will be performed on the entire occlusal and at the hypomineralized areas. (34) The laser tip will pass in a uniform scanning motion steadily for 20 sec with relative isolation with 11% air and no water-cooling system. During the laser treatment, all safety measures will be followed.
Study NCT06801561 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glass ionomer sealant
Description: This group will receive glass ionomer sealant. Conditioning of the surface will be done using polyacrylic acid (10%) conditioner for 20 seconds, then rinsed and dried. Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
Study NCT06800911 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Metacognition Questionnaire Penn State Worry Questionnaire Ruminative Response Scale Anger Rumination scale Difficulties in Emotion Regulation Scale Emotional Eating subscale of the Dutch Eating Behavior Questionnaire
Study NCT06699576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib: 12mg once daily (QD) orally
Study NCT06279364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: IV Infusion
Study NCT06279364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV Infusion.
Study NCT06279364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion.
Study NCT06279364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablet. Oral route of administration.
Study NCT06279364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: IV infusion.
Study NCT06699576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin: administered as an IV infusion
Study NCT06279364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion.
Study NCT05326243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted chimeric antigen receptor T-cell
Description: Drug: Fludarabine~patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Drug: Cyclophosphamide~patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Biological: CD19 CAR-T~CD19 CAR-T cells will be administered using as a single dose at 0.1-9\*10\^6 cells/kg on Day 0 after completion of the lymphodepletion chemotherapy. The body weight calculated for PL001 dose is the actual body weight on the day of leukapheresis.
Study NCT06331546 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-oxalate diet
Description: 4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)
Study NCT06331546 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-oxalate diet
Description: 4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)
Study NCT06331546 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-oxalate diet
Description: 4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium content (600-1000 mg/day)
Study NCT06331546 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-oxalate diet
Description: 4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium content (600-1000 mg/day)
Study NCT06331546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: soluble oxalate gut absorption test
Description: Oral ingestion of 13C2-oxalate and sucralose.
Study NCT06331546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soluble oxalate gut absorption test
Description: Oral ingestion of 13C2-oxalate and sucralose.
Study NCT05380804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cutaneous silent period (CSP) measurement
Description: CSP recordings are performed in the upper extremities using the same surface bar recording electrodes. Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms). Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle. During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed. CSP latency and duration are calculated and recorded. CSP latency is defined as the time between the stimulation and the onset of the silent period. CSP duration is calculated as the time interval between the beginning and end of the CSP.
Study NCT04938232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous infusion
Study NCT04938232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous infusion
Study NCT05823961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-linked hyaluronic acid eye drops
Description: Cross-linked hyaluronic acid (CLHA)-based eyedrops
Study NCT06140927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will be administered ketamine at increasing doses followed by measurements of motor-evoked potentials.
Study NCT05605275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCT levels
Description: All patients will have their serum PCT level recorded on the day of the positive blood culture and in the next three days.
Study NCT05605275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CRP levels
Description: All patients will have their serum CRP level recorded on the day of the positive blood culture and in the next three days.
Study NCT05605275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: White blood cell count
Description: All patients will have their white blood cell (WBC) count recorded on the day of the positive blood culture and in the next three days.
Study NCT05605275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count
Description: All patients will have their platelets count recorded on the day of the positive blood culture and in the next three days.
Study NCT04876924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-711
Description: BBP-711, oral suspension
Study NCT04876924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BBP-711
Study NCT06311201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal belt
Description: This was used for all women in both groups (A and B) for 8 weeks starting from the 7th days after delivery. The women was asked to wear the abdominal belt throughout the day except when bathing, eating and sleeping. The binder was worn over the skin directly or on a thin layer of clothing. The side of the abdominal binder without the straps was pulled over by the woman's stomach with one hand. The side of the binder with straps was stretched across the stomach and pulled to the center of the abdomen. The straps then was fitted into the buckles. Women were instructed not to wear the binder too tight or too loose as it might irritate the skin and produce difficulty in breathing creating discomfort. They were asked to inspect their skin regularly for any signs of sensitivity.
Study NCT06311201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal belt
Description: This was used for all women in both groups (A and B) for 8 weeks starting from the 7th days after delivery. The women was asked to wear the abdominal belt throughout the day except when bathing, eating and sleeping. The binder was worn over the skin directly or on a thin layer of clothing. The side of the abdominal binder without the straps was pulled over by the woman's stomach with one hand. The side of the binder with straps was stretched across the stomach and pulled to the center of the abdomen. The straps then was fitted into the buckles. Women were instructed not to wear the binder too tight or too loose as it might irritate the skin and produce difficulty in breathing creating discomfort. They were asked to inspect their skin regularly for any signs of sensitivity.